We have encountered this in our clinic. We opted for clinical trial referral. The BEACON trial showed an impressive ORR of 48% with encoragenib, binimetinib and cetuximab, however, patients with prior exposure to any RAF or MEK inhibitor, cetuximab, panitumumab, or other EGFR inhibitor were excluded...